Sinoway Industrial Co., Ltd.

Liraglutide 204656-20-2 Liraglutide 204656-20-2

Liraglutide 204656-20-2
Related Products
  • NanoActive alpha lipoic acid (ALA) 1077-28-7

    1.Basic information of NanoActive alpha lipoic acidProduct Name: NanoActive alpha lipoic acid (ALA)Other Names: NanoActive THIOOCTIC ACIDAppearance: yellow, viscous and transparent liquidTest Method: ...

  • NanoActive Astaxanthin 472-61-7

    1.Basic information of NanoActive AstaxanthinProduct Name: NanoActive AstaxanthinOther Names: NanoActive AstaAppearance: reddish to dark red, viscous and transparent liquidTest Method: HPLCCAS NO.: 47...

  • NanoActive Curcumin 458-37-7

    1.Basic information of NanoActive CurcuminProduct Name: NanoActive CurcuminOther Names: NanoActive turmeric extractAppearance: yellow, viscous and transparent liquidTest Method: HPLCCAS NO.: 458-37-7S...

Product Description of Liraglutide 204656-20-2

  • Product Name: Liraglutide
  • Appearance: White to off-white crystalline powder
  • Molecular Formula C172H265N43O51
  • Cas. No.  204656-20-2
  • Molecular Weight   3751.20
  • Storage 2~8℃

Introduction of Liraglutide 204656-20-2

  • Liraglutide (NN2211) is a long-acting glucagon-like peptide-1 receptor agonist, binding to the same receptors as does the endogenous metabolic hormone GLP-1 that stimulates insulin secretion.

Specification of Liraglutide 204656-20-2

Product Name:

Liraglutide

Sequence:

H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-

Glu-Gly-Gln-Ala-Ala-Lys[N6-[N-(1-oxohexadecyl)-L-γ-glutamyl]-

-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH

Lot No.:

140601

Release Date:

2014-6-13



Test

Specification

Results

Appearance:

White to off-white crystalline powder or lumps

White powder

Identity:

3751.2±1.0

3751.1

Purity (By HPLC) :

Not Less than 98.0%;

99.51%

Residual solvents:

≤0.25%total; ≤0.1%individual;

≤0.01%CH2CN

Complies

Related Peptide

Total Impurity ≤ 2.0%

Largest Single Impurity ≤ 1.0%

TI =0.41%

LSI =0.25%

Peptide Content:

Not Less than 85.0%

87.7%

Water (K.F.):

Not more than 5%

4.2%

Acetate acid:

Not more than 10%

8.1%

Bacterial Endotoxins

Not more than 50IU/mg

Complies


Function and Usage of Liraglutide 204656-20-2

Type 2 diabetes
Liraglutide improves control of blood glucose.It reduces meal-related hyperglycemia (for 24 hours after administration) by increasing insulin secretion (only) when required by increasing glucose levels, delaying gastric emptying, and suppressing prandial glucagon secretion.
In common to various degrees with other GLP-1 receptor agonists, liraglutide has advantages over more traditional therapies for type 2 diabetes:
  • It acts in a glucose-dependent manner, meaning it will stimulate insulin secretion only when blood glucose levels are higher than normal, preventing "overshoot". Consequently, it shows negligible risk of hypoglycemia.
  • It has the potential for inhibiting apoptosis and stimulating regeneration of beta cells (seen in animal studies).
  • It decreases appetite and inhibits body weight gain, as shown in a head-to-head study versus glimepiride.
  • It lowers blood triglyceride levels.
Obesity
Liraglutide has been approved as an injectable adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients. The specified criteria are an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight), in the presence of at least one weight-related comorbid condition (e.g.hypertension, type 2 diabetes mellitus, or dyslipidemia). In late 2014, data were reported from the SCALE™ Obesity and Prediabetes trial, which is a randomised, double-blind, placebo-controlled, multinational trial in non-diabetic people with obesity and non-diabetic people who are overweight with comorbidities. In this phase 3a trial, there were 3,731 participants randomised to treatment with liraglutide 3 mg or placebo, both in combination with diet and exercise. Those who completed the 56-week trial achieved an average weight loss of 9.2%, to be compared with a 3.5% reduction in the placebo group.


MORE_DETAIL Liraglutide 204656-20-2

Product Description of Liraglutide 204656-20-2

  • Product Name: Liraglutide
  • Appearance: White to off-white crystalline powder
  • Molecular Formula C172H265N43O51
  • Cas. No.  204656-20-2
  • Molecular Weight   3751.20
  • Storage 2~8℃

Introduction of Liraglutide 204656-20-2

  • Liraglutide (NN2211) is a long-acting glucagon-like peptide-1 receptor agonist, binding to the same receptors as does the endogenous metabolic hormone GLP-1 that stimulates insulin secretion.

Specification of Liraglutide 204656-20-2

Product Name:

Liraglutide

Sequence:

H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-

Glu-Gly-Gln-Ala-Ala-Lys[N6-[N-(1-oxohexadecyl)-L-γ-glutamyl]-

-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH

Lot No.:

140601

Release Date:

2014-6-13



Test

Specification

Results

Appearance:

White to off-white crystalline powder or lumps

White powder

Identity:

3751.2±1.0

3751.1

Purity (By HPLC) :

Not Less than 98.0%;

99.51%

Residual solvents:

≤0.25%total; ≤0.1%individual;

≤0.01%CH2CN

Complies

Related Peptide

Total Impurity ≤ 2.0%

Largest Single Impurity ≤ 1.0%

TI =0.41%

LSI =0.25%

Peptide Content:

Not Less than 85.0%

87.7%

Water (K.F.):

Not more than 5%

4.2%

Acetate acid:

Not more than 10%

8.1%

Bacterial Endotoxins

Not more than 50IU/mg

Complies


Function and Usage of Liraglutide 204656-20-2

Type 2 diabetes
Liraglutide improves control of blood glucose.It reduces meal-related hyperglycemia (for 24 hours after administration) by increasing insulin secretion (only) when required by increasing glucose levels, delaying gastric emptying, and suppressing prandial glucagon secretion.
In common to various degrees with other GLP-1 receptor agonists, liraglutide has advantages over more traditional therapies for type 2 diabetes:
  • It acts in a glucose-dependent manner, meaning it will stimulate insulin secretion only when blood glucose levels are higher than normal, preventing "overshoot". Consequently, it shows negligible risk of hypoglycemia.
  • It has the potential for inhibiting apoptosis and stimulating regeneration of beta cells (seen in animal studies).
  • It decreases appetite and inhibits body weight gain, as shown in a head-to-head study versus glimepiride.
  • It lowers blood triglyceride levels.
Obesity
Liraglutide has been approved as an injectable adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients. The specified criteria are an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight), in the presence of at least one weight-related comorbid condition (e.g.hypertension, type 2 diabetes mellitus, or dyslipidemia). In late 2014, data were reported from the SCALE™ Obesity and Prediabetes trial, which is a randomised, double-blind, placebo-controlled, multinational trial in non-diabetic people with obesity and non-diabetic people who are overweight with comorbidities. In this phase 3a trial, there were 3,731 participants randomised to treatment with liraglutide 3 mg or placebo, both in combination with diet and exercise. Those who completed the 56-week trial achieved an average weight loss of 9.2%, to be compared with a 3.5% reduction in the placebo group.

Related Articles
Leave a Message Email Us

we will contact you within 24 hours.

  • TEL:+86-0592-5854962
  • FAX:+86-0592-5854960
  • EMAIL: xie@china-sinoway.com
  • ADDRESS:Floor 16, Huicheng Business Center, No. 839, Xiahe Rd., Siming Dist. Xiamen, Fujian, China
//